Casopitant
Encyclopedia
Casopitant is an neurokinin 1 (NK1) receptor antagonist
undergoing research for the treatment of chemotherapy-induced nausea and vomiting
(CINV). It is currently under development by GlaxoSmithKline
(GSK).
In July 2008, the company filed a marketing authorisation application with the European Medicines Agency
. The application was withdrawn in September 2009 because GSK decided that further safety assessment was necessary.
Receptor antagonist
A receptor antagonist is a type of receptor ligand or drug that does not provoke a biological response itself upon binding to a receptor, but blocks or dampens agonist-mediated responses...
undergoing research for the treatment of chemotherapy-induced nausea and vomiting
Chemotherapy-induced nausea and vomiting
Chemotherapy-induced nausea and vomiting is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families. In 1983, Coates et al. found that patients receiving chemotherapy ranked nausea...
(CINV). It is currently under development by GlaxoSmithKline
GlaxoSmithKline
GlaxoSmithKline plc is a global pharmaceutical, biologics, vaccines and consumer healthcare company headquartered in London, United Kingdom...
(GSK).
In July 2008, the company filed a marketing authorisation application with the European Medicines Agency
European Medicines Agency
The European Medicines Agency is a European agency for the evaluation of medicinal products. From 1995 to 2004, the European Medicines Agency was known as European Agency for the Evaluation of Medicinal Products.Roughly parallel to the U.S...
. The application was withdrawn in September 2009 because GSK decided that further safety assessment was necessary.